Dr. Reddy's Laboratories received approval of XEGLYZE™ (abametapir) lotion, 0.74%, in the U.S.

Shares of DR.REDDY'sDr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as "Dr. Reddy's") today announced approval of XEGLYZE (abametapir) lotion, 0.74%, a 505(b)(1) NDA by the U.S. Food and Drug Administration (USFDA). The approval triggers the contractual precommercialization milestone of $20 million payable to Hatchtech Pty Ltd. XEGLYZE is indicated for the topical treatment of head lice infestation in patients 6 months of age and older. The company is working to commercialize this product through partners.

INDICATION AND USAGE

XEGLYZE is indicated for the topical treatment of head lice infestation in patients 6 months of age and older.

XEGLYZE should be used in the context of an overall lice management program:

- Wash (with hot water) or dry-clean all recently worn clothing, hats, used bedding and towels.

- Wash personal care items such as combs, brushes, and hair clips in hot water.

Use a fine-tooth comb or special nit comb to remove dead lice and nits. LABORATORIES LTD. was last trading in BSE at Rs.4063.7 as compared to the previous close of Rs. 4128.55. The total number of shares traded during the day was 37440 in over 3464 trades.

The stock hit an intraday high of Rs. 4179.35 and intraday low of 4054. The net turnover during the day was Rs. 154106892.

Source : Equity Bulls

Keywords